Hospital Medicine

Majid M. Mughal, MD
Assistant Professor of Medicine, University of South Alabama Medical Center, Mobile

Daniel A. Culver, DO
Department of Pulmonary, Allergy, and Critical Care Medicine, The Cleveland Clinic Foundation

Omar A. Minai, MD
Department of Pulmonary, Allergy, and Critical Care Medicine, The Cleveland Clinic Foundation

Alejandro C. Arroliga, MD
Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western University; Head, Section of Critical Care Medicine, Department of Pulmonary, Allergy, and Critical Care Medicine, The Cleveland Clinic Foundation

Address: Majid Mughal, MD, University of South Alabama Medical Center, 2451 Fillingim Street, Mobile, AL 36617-2293

Majid M. Mughal, MD
Assistant Professor of Medicine, University of South Alabama Medical Center, Mobile

Daniel A. Culver, DO
Department of Pulmonary, Allergy, and Critical Care Medicine, The Cleveland Clinic Foundation

Omar A. Minai, MD
Department of Pulmonary, Allergy, and Critical Care Medicine, The Cleveland Clinic Foundation

Alejandro C. Arroliga, MD
Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western University; Head, Section of Critical Care Medicine, Department of Pulmonary, Allergy, and Critical Care Medicine, The Cleveland Clinic Foundation

Address: Majid Mughal, MD, University of South Alabama Medical Center, 2451 Fillingim Street, Mobile, AL 36617-2293

Majid M. Mughal, MD
Assistant Professor of Medicine, University of South Alabama Medical Center, Mobile

Daniel A. Culver, DO
Department of Pulmonary, Allergy, and Critical Care Medicine, The Cleveland Clinic Foundation

Omar A. Minai, MD
Department of Pulmonary, Allergy, and Critical Care Medicine, The Cleveland Clinic Foundation

Alejandro C. Arroliga, MD
Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western University; Head, Section of Critical Care Medicine, Department of Pulmonary, Allergy, and Critical Care Medicine, The Cleveland Clinic Foundation

Address: Majid Mughal, MD, University of South Alabama Medical Center, 2451 Fillingim Street, Mobile, AL 36617-2293

Christopher M. Whinney, MD
Section of Hospital and Preoperative Medicine, Department of General Internal Medicine, The Cleveland Clinic Foundation

Address: Christopher M. Whinney, MD, Section of Hospital and Preoperative Medicine, Department of General Internal Medicine, E13, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail [email protected]

Christopher M. Whinney, MD
Section of Hospital and Preoperative Medicine, Department of General Internal Medicine, The Cleveland Clinic Foundation

Address: Christopher M. Whinney, MD, Section of Hospital and Preoperative Medicine, Department of General Internal Medicine, E13, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail [email protected]

Christopher M. Whinney, MD
Section of Hospital and Preoperative Medicine, Department of General Internal Medicine, The Cleveland Clinic Foundation

Address: Christopher M. Whinney, MD, Section of Hospital and Preoperative Medicine, Department of General Internal Medicine, E13, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail [email protected]

Ravindran A. Padmanabhan, MD
Department of Infectious Diseases, The Cleveland Clinic Foundation

Thomas G. Fraser, MD
Department of Infectious Diseases, The Cleveland Clinic Foundation

Address: Thomas G. Fraser, MD, FACP, Department of Infectious Diseases, S32, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail [email protected]

Ravindran A. Padmanabhan, MD
Department of Infectious Diseases, The Cleveland Clinic Foundation

Thomas G. Fraser, MD
Department of Infectious Diseases, The Cleveland Clinic Foundation

Address: Thomas G. Fraser, MD, FACP, Department of Infectious Diseases, S32, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail [email protected]

Ravindran A. Padmanabhan, MD
Department of Infectious Diseases, The Cleveland Clinic Foundation

Thomas G. Fraser, MD
Department of Infectious Diseases, The Cleveland Clinic Foundation

Address: Thomas G. Fraser, MD, FACP, Department of Infectious Diseases, S32, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail [email protected]

L. Bernardo Menajovsky, MD, MS
Jefferson Antithrombotic Therapy Service, Department of Internal Medicine, Thomas Jefferson University, Philadelphia, PA

John Spandorfer, MD
Jefferson Antithrombotic Therapy Service, Department of Internal Medicine, Thomas Jefferson University, Philadelphia, PA

Address: L. Bernardo Menajovsky, MD, MS, Thomas Jefferson Thomas Jefferson University Hospital, 833 Chestnut Street East, Suite 701, Philadelphia, PA 19107; e-mail [email protected]

Dr. Menajovsky has indicated that he is on the speakers’ bureau of the Aventis corporation.

Dr. Spandorfer has indicated that he has received grant or research support from the Aventis and Astra Zeneca corporations and is on the speakers’ bureaus of the Aventis and Astra Zeneca corporations.

This paper discusses therapies that are experimental or that are not approved by the US Food and Drug Administration for the use under discussion.

L. Bernardo Menajovsky, MD, MS
Jefferson Antithrombotic Therapy Service, Department of Internal Medicine, Thomas Jefferson University, Philadelphia, PA

John Spandorfer, MD
Jefferson Antithrombotic Therapy Service, Department of Internal Medicine, Thomas Jefferson University, Philadelphia, PA

Address: L. Bernardo Menajovsky, MD, MS, Thomas Jefferson Thomas Jefferson University Hospital, 833 Chestnut Street East, Suite 701, Philadelphia, PA 19107; e-mail [email protected]

Dr. Menajovsky has indicated that he is on the speakers’ bureau of the Aventis corporation.

Dr. Spandorfer has indicated that he has received grant or research support from the Aventis and Astra Zeneca corporations and is on the speakers’ bureaus of the Aventis and Astra Zeneca corporations.

This paper discusses therapies that are experimental or that are not approved by the US Food and Drug Administration for the use under discussion.

L. Bernardo Menajovsky, MD, MS
Jefferson Antithrombotic Therapy Service, Department of Internal Medicine, Thomas Jefferson University, Philadelphia, PA

John Spandorfer, MD
Jefferson Antithrombotic Therapy Service, Department of Internal Medicine, Thomas Jefferson University, Philadelphia, PA

Address: L. Bernardo Menajovsky, MD, MS, Thomas Jefferson Thomas Jefferson University Hospital, 833 Chestnut Street East, Suite 701, Philadelphia, PA 19107; e-mail [email protected]

Dr. Menajovsky has indicated that he is on the speakers’ bureau of the Aventis corporation.

Dr. Spandorfer has indicated that he has received grant or research support from the Aventis and Astra Zeneca corporations and is on the speakers’ bureaus of the Aventis and Astra Zeneca corporations.

This paper discusses therapies that are experimental or that are not approved by the US Food and Drug Administration for the use under discussion.

Sharon K. Inouye, MD, MPH
Department of Internal Medicine, Yale University School of Medicine

Address: Sharon K Inouye, MD, MPH, Department of Internal Medicine, Yale University School of Medicine, 333 Cedar Street (DC013K), PO Box 208025, New Haven, CT 06520

This paper was adapted from a presentation given by Dr. Inouye as Visiting Professor Pro Tempore, Department of Medicine, Case Western Reserve University and The Cleveland Clinic Educational Foundation.

Medical Grand Rounds articles are approved by the author but are not peer-reviewed.

Sharon K. Inouye, MD, MPH
Department of Internal Medicine, Yale University School of Medicine

Address: Sharon K Inouye, MD, MPH, Department of Internal Medicine, Yale University School of Medicine, 333 Cedar Street (DC013K), PO Box 208025, New Haven, CT 06520

This paper was adapted from a presentation given by Dr. Inouye as Visiting Professor Pro Tempore, Department of Medicine, Case Western Reserve University and The Cleveland Clinic Educational Foundation.

Medical Grand Rounds articles are approved by the author but are not peer-reviewed.

Sharon K. Inouye, MD, MPH
Department of Internal Medicine, Yale University School of Medicine

Address: Sharon K Inouye, MD, MPH, Department of Internal Medicine, Yale University School of Medicine, 333 Cedar Street (DC013K), PO Box 208025, New Haven, CT 06520

This paper was adapted from a presentation given by Dr. Inouye as Visiting Professor Pro Tempore, Department of Medicine, Case Western Reserve University and The Cleveland Clinic Educational Foundation.

Medical Grand Rounds articles are approved by the author but are not peer-reviewed.

John D. Clough, MD
Editor in Chief

John D. Clough, MD
Editor in Chief

John D. Clough, MD
Editor in Chief

Etie Moghissi, MD
Medical Director, Diabetes Care Center at Centinela Hospital, Inglewood, CA; Co-chair, American College of Endocrinology Task Force on Inpatient Diabetes and Metabolic Control

Address: Etie Moghissi, MD, FACE, Medical Director, Diabetes Care Center at Centinela Hospital, 501 East Hardy Street, Suite 110, Inglewood, CA 90301; e-mail [email protected]

The author has indicated that she is on the speakers’ bureaus of the GlaxoSmithKline, Novo Nordisk, and Pfizer corporations.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Etie Moghissi, MD
Medical Director, Diabetes Care Center at Centinela Hospital, Inglewood, CA; Co-chair, American College of Endocrinology Task Force on Inpatient Diabetes and Metabolic Control

Address: Etie Moghissi, MD, FACE, Medical Director, Diabetes Care Center at Centinela Hospital, 501 East Hardy Street, Suite 110, Inglewood, CA 90301; e-mail [email protected]

The author has indicated that she is on the speakers’ bureaus of the GlaxoSmithKline, Novo Nordisk, and Pfizer corporations.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Etie Moghissi, MD
Medical Director, Diabetes Care Center at Centinela Hospital, Inglewood, CA; Co-chair, American College of Endocrinology Task Force on Inpatient Diabetes and Metabolic Control

Address: Etie Moghissi, MD, FACE, Medical Director, Diabetes Care Center at Centinela Hospital, 501 East Hardy Street, Suite 110, Inglewood, CA 90301; e-mail [email protected]

The author has indicated that she is on the speakers’ bureaus of the GlaxoSmithKline, Novo Nordisk, and Pfizer corporations.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Josef Stehlik, MD, MPH
Section of Heart Failure and Transplantation, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation

David O. Taylor, MD
Director, Heart Failure Special Care Unit, The Cleveland Clinic Foundation

Address: David Taylor, MD, Department of Cardiovascular Medicine, F25, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Josef Stehlik, MD, MPH
Section of Heart Failure and Transplantation, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation

David O. Taylor, MD
Director, Heart Failure Special Care Unit, The Cleveland Clinic Foundation

Address: David Taylor, MD, Department of Cardiovascular Medicine, F25, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Josef Stehlik, MD, MPH
Section of Heart Failure and Transplantation, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation

David O. Taylor, MD
Director, Heart Failure Special Care Unit, The Cleveland Clinic Foundation

Address: David Taylor, MD, Department of Cardiovascular Medicine, F25, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195